MMJ Bio Science has become the first company to obtain a Canadian license to produce medical cannabis, with the initial authorization covering products for multiple sclerosis and Huntington’s disease.
The Health Canada license allows the company to extract cannabinoids from plants that it grows to produce therapies that will be tested in U.S. Food and Drug Administration-approved studies.
MMJ is pursuing orphan drug status in the U.S. for MMJ-001, the company’s lead product, a cannabidiol (CBD) derivative and treatment candidate for MS patients. CBD and tetrahydrocanabinol (THC) are the most abundant cannabinoids in cannabis.
The company also wants to obtain orphan drug status for MMJ-102, its therapy for Huntington’s disease.
The FDA grants orphan drug status to medications intended for the safe and effective treatment, diagnosis or prevention of diseases that affect fewer than 200,000 people in the U.S. The status also applies to drugs that affect more than 200,000 patients but are